IDEAS home Printed from https://ideas.repec.org/p/pra/mprapa/57761.html
   My bibliography  Save this paper

Economic Impact of Dengue Illness and the Cost-Effectiveness of Future Vaccination Programs in Singapore

Author

Listed:
  • Carrasco, Luis R
  • Lee, Linda K
  • Lee, Vernon J
  • Ooi, Eng Eong
  • Shepard, Donald S
  • Thein, Tun L
  • Gan, Victor
  • Cook, Alex R
  • Lye, David
  • Ng, Lee Ching
  • Leo, Yee Sin

Abstract

Background: Dengue illness causes 50–100 million infections worldwide and threatens 2.5 billion people in the tropical and subtropical regions. Little is known about the disease burden and economic impact of dengue in higher resourced countries or the cost-effectiveness of potential dengue vaccines in such settings. Methods and Findings: We estimate the direct and indirect costs of dengue from hospitalized and ambulatory cases in Singapore. We consider inter alia the impacts of dengue on the economy using the human-capital and the friction cost methods. Disease burden was estimated using disability-adjusted life years (DALYs) and the cost-effectiveness of a potential vaccine program was evaluated. The average economic impact of dengue illness in Singapore from 2000 to 2009 in constant 2010 US$ ranged between $0.85 billion and $1.15 billion, of which control costs constitute 42%–59%. Using empirically derived disability weights, we estimated an annual average disease burden of 9–14 DALYs per 100 000 habitants, making it comparable to diseases such as hepatitis B or syphilis. The proportion of symptomatic dengue cases detected by the national surveillance system was estimated to be low, and to decrease with age. Under population projections by the United Nations, the price per dose threshold for which vaccines stop being more cost-effective than the current vector control program ranged from $50 for mass vaccination requiring 3 doses and only conferring 10 years of immunity to $300 for vaccination requiring 2 doses and conferring lifetime immunity. The thresholds for these vaccine programs to not be cost-effective for Singapore were $100 and $500 per dose respectively. Conclusions: Dengue illness presents a serious economic and disease burden in Singapore. Dengue vaccines are expected to be cost-effective if reasonably low prices are adopted and will help to reduce the economic and disease burden of dengue in Singapore substantially.

Suggested Citation

  • Carrasco, Luis R & Lee, Linda K & Lee, Vernon J & Ooi, Eng Eong & Shepard, Donald S & Thein, Tun L & Gan, Victor & Cook, Alex R & Lye, David & Ng, Lee Ching & Leo, Yee Sin, 2011. "Economic Impact of Dengue Illness and the Cost-Effectiveness of Future Vaccination Programs in Singapore," MPRA Paper 57761, University Library of Munich, Germany.
    • Handle: RePEc:pra:mprapa:57761
    as

    Download full text from publisher

    File URL: https://mpra.ub.uni-muenchen.de/57761/1/MPRA_paper_57761.pdf
    File Function: original version
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Keating, Joseph, 2001. "An investigation into the cyclical incidence of dengue fever," Social Science & Medicine, Elsevier, vol. 53(12), pages 1587-1597, December.
    2. Koopmanschap, Marc A. & Rutten, Frans F. H. & van Ineveld, B. Martin & van Roijen, Leona, 1995. "The friction cost method for measuring indirect costs of disease," Journal of Health Economics, Elsevier, vol. 14(2), pages 171-189, June.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Le T P Nghiem & Tarek Soliman & Darren C J Yeo & Hugh T W Tan & Theodore A Evans & John D Mumford & Reuben P Keller & Richard H A Baker & Richard T Corlett & Luis R Carrasco, 2013. "Economic and Environmental Impacts of Harmful Non-Indigenous Species in Southeast Asia," PLOS ONE, Public Library of Science, vol. 8(8), pages 1-9, August.
    2. Eunha Shim, 2017. "Cost-effectiveness of dengue vaccination in Yucatán, Mexico using a dynamic dengue transmission model," PLOS ONE, Public Library of Science, vol. 12(4), pages 1-17, April.
    3. Eduardo A Undurraga & Yara A Halasa & Donald S Shepard, 2013. "Use of Expansion Factors to Estimate the Burden of Dengue in Southeast Asia: A Systematic Analysis," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 7(2), pages 1-15, February.
    4. Christopher Fitzpatrick & Alexander Haines & Mathieu Bangert & Andrew Farlow & Janet Hemingway & Raman Velayudhan, 2017. "An economic evaluation of vector control in the age of a dengue vaccine," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 11(8), pages 1-27, August.
    5. Nghiem, Le T.P. & Soliman, Tarek & Yeo, Darren C. J. & Tan, Hugh T. W. & Evans, Theodore A. & Mumford, John D. & Keller, Reuben P. & Baker, Richard H. A. & Corlett, Richard T. & Carrasco, Luis R., 2013. "Economic and Environmental Impacts of Harmful Non-Indigenous Species in Southeast Asia," MPRA Paper 57760, University Library of Munich, Germany.
    6. Dagna Constenla & Cristina Garcia & Noah Lefcourt, 2015. "Assessing the Economics of Dengue: Results from a Systematic Review of the Literature and Expert Survey," PharmacoEconomics, Springer, vol. 33(11), pages 1107-1135, November.
    7. Gerhart Knerer & Christine S M Currie & Sally C Brailsford, 2020. "The economic impact and cost-effectiveness of combined vector-control and dengue vaccination strategies in Thailand: results from a dynamic transmission model," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 14(10), pages 1-32, October.
    8. Donald S Shepard & Eduardo A Undurraga & Yara A Halasa, 2013. "Economic and Disease Burden of Dengue in Southeast Asia," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 7(2), pages 1-12, February.
    9. Ong, Suan Ee & Tyagi, Shilpa & Lim, Jane Mingjie & Chia, Kee Seng & Legido-Quigley, Helena, 2018. "Health systems reforms in Singapore: A qualitative study of key stakeholders," Health Policy, Elsevier, vol. 122(4), pages 431-443.
    10. May Ee Png & Joanne Su-Yin Yoong, 2014. "Evaluating the Cost-Effectiveness of Lifestyle Modification versus Metformin Therapy for the Prevention of Diabetes in Singapore," PLOS ONE, Public Library of Science, vol. 9(9), pages 1-8, September.
    11. Gabueva, Larisa A. (Габуева, Лариса) & Pavlova, Nina F. (Павлова, Нина), 2017. "Foreign and Domestic Trends in the Development of Competition in Health Care: Recognition and Measurement of Professional Reputation [Зарубежные И Отечественные Тренды Развития Конкуренции В Здраво," Working Papers 021705, Russian Presidential Academy of National Economy and Public Administration.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Luis R Carrasco & Linda K Lee & Vernon J Lee & Eng Eong Ooi & Donald S Shepard & Tun L Thein & Victor Gan & Alex R Cook & David Lye & Lee Ching Ng & Yee Sin Leo, 2011. "Economic Impact of Dengue Illness and the Cost-Effectiveness of Future Vaccination Programs in Singapore," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 5(12), pages 1-9, December.
    2. Iris Arends & Ute Bültmann & Willem van Rhenen & Henk Groen & Jac J L van der Klink, 2013. "Economic Evaluation of a Problem Solving Intervention to Prevent Recurrent Sickness Absence in Workers with Common Mental Disorders," PLOS ONE, Public Library of Science, vol. 8(8), pages 1-1, August.
    3. Anne Tiainen & Clas Rehnberg, 2010. "The Economic Burden of Psychiatric Disorders in Sweden," International Journal of Social Psychiatry, , vol. 56(5), pages 515-526, September.
    4. Tilling, C & Krol, M & Tsuchiya, A & Brazier, J & van Exel, J & Brouwer, W, 2009. "The impact of losses in income due to ill health: does the EQ-5D reflect lost earnings?," MPRA Paper 29837, University Library of Munich, Germany.
    5. Phaisarn Jeefoo & Nitin Kumar Tripathi & Marc Souris, 2010. "Spatio-Temporal Diffusion Pattern and Hotspot Detection of Dengue in Chachoengsao Province, Thailand," IJERPH, MDPI, vol. 8(1), pages 1-24, December.
    6. Hanly, Paul & Ortega Ortega, Marta & Pearce, Alison & Soerjomataram, Isabelle & Sharp, Linda, 2020. "Advances in the methodological approach to friction period estimation: A European perspective," Social Science & Medicine, Elsevier, vol. 264(C).
    7. Siri Fauli & Geir Thue, 2008. "Economic consequences of near-patient test results: the case of tests for the Helicobacter Pylori bacterium in dyspepsia," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 9(3), pages 221-228, August.
    8. Paul Hanly & Rebecca Maguire & Frances Drummond & Linda Sharp, 2019. "Variation in the methodological approach to productivity cost valuation: the case of prostate cancer," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(9), pages 1399-1408, December.
    9. Jonathan Karnon & Jill Carlton & Carolyn Czoski-Murray & Kevin Smith, 2009. "Informing disinvestment through cost-effectiveness modelling," Applied Health Economics and Health Policy, Springer, vol. 7(1), pages 1-9, March.
    10. Thomas DeLeire & Willard Manning, 2004. "Labor market costs of illness: prevalence matters," Health Economics, John Wiley & Sons, Ltd., vol. 13(3), pages 239-250, March.
    11. Tobias Effertz & Susanne Engel & Frank Verheyen & Roland Linder, 2016. "The costs and consequences of obesity in Germany: a new approach from a prevalence and life-cycle perspective," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(9), pages 1141-1158, December.
    12. Allison Larg & John Moss, 2011. "Cost-of-Illness Studies," PharmacoEconomics, Springer, vol. 29(8), pages 653-671, August.
    13. Klose, Thomas, 1999. "The contingent valuation method in health care," Health Policy, Elsevier, vol. 47(2), pages 97-123, May.
    14. Annie Hawton & James Shearer & Elizabeth Goodwin & Colin Green, 2013. "Squinting Through Layers of Fog: Assessing the Cost Effectiveness of Treatments for Multiple Sclerosis," Applied Health Economics and Health Policy, Springer, vol. 11(4), pages 331-341, August.
    15. Foster, Nicola & Vassall, Anna & Cleary, Susan & Cunnama, Lucy & Churchyard, Gavin & Sinanovic, Edina, 2015. "The economic burden of TB diagnosis and treatment in South Africa," Social Science & Medicine, Elsevier, vol. 130(C), pages 42-50.
    16. Antoine Bailly & Et Carole Chichignoud, 2006. "Risques Et Santé/Riesgos Y Salud," Estudios de Economia Aplicada, Estudios de Economia Aplicada, vol. 24, pages 865-874, Diciembre.
    17. Hansen, Kristian S. & Moreno-Ternero, Juan D. & Østerdal, Lars P., 2024. "Quality- and productivity-adjusted life years: From QALYs to PALYs and beyond," Journal of Health Economics, Elsevier, vol. 95(C).
    18. Orsolya Balogh & Valentin Brodszky & László Gulácsi & Emese Herédi & Krisztina Herszényi & Hajnalka Jókai & Sarolta Kárpáti & Petra Baji & Éva Remenyik & Andrea Szegedi & Péter Holló, 2014. "Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 101-109, May.
    19. Marie Kruse & Jan Sørensen & Dorte Gyrd-Hansen, 2012. "Future costs in cost-effectiveness analysis: an empirical assessment," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(1), pages 63-70, February.
    20. James Shearer & Paul McCrone & Renee Romeo, 2016. "Economic Evaluation of Mental Health Interventions: A Guide to Costing Approaches," PharmacoEconomics, Springer, vol. 34(7), pages 651-664, July.

    More about this item

    Keywords

    Health Economics; Dengue Vaccines; Cost-Effective Analysis;
    All these keywords.

    JEL classification:

    • I10 - Health, Education, and Welfare - - Health - - - General
    • I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
    • I19 - Health, Education, and Welfare - - Health - - - Other

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:pra:mprapa:57761. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Joachim Winter (email available below). General contact details of provider: https://edirc.repec.org/data/vfmunde.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.